Abstract 496: Oncolinkage: Discovery of tumor-selective surface targets for cancer therapy.

Abstract Cancer therapeutics such as CAR T, Radioligand , ADC, and Bispecifics are all reliant on targeting cancer-selective surface proteins. A major limitation to these tethered killing strategies is the lack of targets that are exclusively expressed on tumor cells and not healthy tissues. Most cancer surface targets exhibit “lineage” expression properties, in which expression is shared by both the tumor and the normal tissue lineage from which the tumor developed. In many cases, expression in